{"id":34255,"date":"2026-01-05T17:38:00","date_gmt":"2026-01-05T12:08:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34255"},"modified":"2026-01-05T15:39:17","modified_gmt":"2026-01-05T10:09:17","slug":"omeros-yartemlea-for-ta-tma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma","title":{"rendered":"FDA Approves Omeros&#8217; YARTEMLEA: A Breakthrough for Stem Cell Transplant Patients Facing TA-TMA"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d713812594a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d713812594a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma\/#Understanding_TA-TMA_A_Rare_but_Devastating_Complication\" >Understanding TA-TMA: A Rare but Devastating Complication<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma\/#YARTEMLEAs_Novel_Mechanism_Targeting_the_Root_Cause\" >YARTEMLEA&#8217;s Novel Mechanism: Targeting the Root Cause<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma\/#Competitive_Landscape_and_First-Mover_Advantage\" >Competitive Landscape and First-Mover Advantage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma\/#Key_Takeaway_A_New_Era_in_Transplant_Care\" >Key Takeaway: A New Era in Transplant Care<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The FDA has approved <strong>YARTEMLEA (narsoplimab-wuug)<\/strong>, marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine. <strong>Omeros Corporation&#8217;s<\/strong> therapeutic advance represents the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This life-threatening complication has historically lacked effective medical interventions and claimed hundreds of lives annually.<\/p>\n\n\n\n<p>For transplant physicians and their patients, this approval signals a fundamental shift in clinical practice\u2014from managing a fatal disease with supportive measures to wielding a targeted therapy with robust efficacy and survival benefit.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-understanding-ta-tma-a-rare-but-devastating-complication\"><span class=\"ez-toc-section\" id=\"Understanding_TA-TMA_A_Rare_but_Devastating_Complication\"><\/span><strong>Understanding TA-TMA: A Rare but Devastating Complication<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>TA-TMA emerges as a systemic consequence of conditioning regimens, immunosuppression, and the transplant process itself. The condition is characterized by endothelial cell injury, complement pathway activation, and microangiopathic hemolytic anemia, leading to multi-organ dysfunction and failure. The clinical picture is grim: mortality in severe TA-TMA can exceed 90%, with survivors often facing chronic kidney disease and dialysis dependence.<\/p>\n\n\n\n<p>The disease burden is substantial. Approximately <strong>30,000<\/strong> allogeneic stem cell transplants are performed annually in the United States and Europe. Recent epidemiological studies estimate that TA-TMA develops in up to 56% of allogeneic transplant recipients, translating to roughly <strong>12,000-18,000<\/strong> patients per year facing this complication. Despite its prevalence and lethality, until now, no FDA-approved therapy existed.<\/p>\n\n\n\n<p><em>Dr. Miguel-Angel Perales, Chief of Adult Bone Marrow Transplantation at Memorial Sloan Kettering, underscored the clinical vacuum: &#8220;Until now, we&#8217;ve lacked an effective TA-TMA therapy and relied largely on supportive measures such as modifying calcineurin inhibitors, which can significantly increase the risk of life-threatening graft-versus-host disease.&#8221;<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-yartemlea-s-novel-mechanism-targeting-the-root-cause\"><span class=\"ez-toc-section\" id=\"YARTEMLEAs_Novel_Mechanism_Targeting_the_Root_Cause\"><\/span><strong>YARTEMLEA&#8217;s Novel Mechanism: Targeting the Root Cause<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>YARTEMLEA&#8217;s therapeutic approach differs fundamentally from symptomatic management. The drug is a fully human monoclonal antibody that selectively inhibits MASP-2 (mannan-binding lectin-associated serine protease-2), the key effector enzyme of the lectin pathway of the complement system.<\/p>\n\n\n\n<p>In TA-TMA pathophysiology, the lectin pathway becomes aberrantly activated by tissue damage and systemic endothelial injury, triggering a cascade of complement-mediated inflammation, cellular damage, and microvascular thrombosis. By blocking MASP-2, YARTEMLEA interrupts this cascade at its source\u2014while critically, it preserves the classical and alternative complement pathways, maintaining the patient&#8217;s adaptive immune response and host defense mechanisms. This selective inhibition provides a therapeutic advantage: treatment addresses the core complement dysregulation driving TA-TMA without compromising infection-fighting capacity.<\/p>\n\n\n\n<p>YARTEMLEA&#8217;s approval journey was not linear. The FDA issued a complete response letter in 2021, requesting additional efficacy and safety data. Omeros subsequently conducted an expanded access program and provided additional analyses of external registry data, ultimately securing approval on December 24, 2025. This approval establishes several regulatory precedents: the drug received breakthrough therapy and orphan drug designations from the FDA, and the EMA granted orphan drug status with a regulatory decision expected in mid-2026. YARTEMLEA&#8217;s FDA approval rested on a robust clinical data package comprising a pivotal open-label trial and an extensive expanded access program.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"364\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/YARTEMLEA-Development-Timeline-1024x364.webp\" alt=\"YARTEMLEA-Development-Timeline\" class=\"wp-image-34258\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/YARTEMLEA-Development-Timeline-1024x364.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/YARTEMLEA-Development-Timeline-300x107.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/YARTEMLEA-Development-Timeline-150x53.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/YARTEMLEA-Development-Timeline-768x273.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/YARTEMLEA-Development-Timeline-1536x546.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/YARTEMLEA-Development-Timeline.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Pivotal Study Results (N=28 adult patients):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Complete Response Rate: 61% (defined as improvement in laboratory markers\u2014platelet counts and LDH levels\u2014plus either improved organ function or transfusion independence)<\/li>\n\n\n\n<li>100-Day Survival: 73% (95% CI: 52\u201386%)<\/li>\n\n\n\n<li>Patient Population: All patients met international criteria for high-risk TA-TMA with poor prognosis<\/li>\n<\/ul>\n\n\n\n<p><strong>Expanded Access Program Data (N=221 total; 19 evaluable for efficacy):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Complete Response Rate: 68%<\/li>\n\n\n\n<li>100-Day Survival: 74% (95% CI: 48\u201388%)<\/li>\n\n\n\n<li>Notable Finding: YARTEMLEA demonstrated efficacy both as first-line therapy and in patients who had previously failed other complement-targeted treatments<\/li>\n<\/ul>\n\n\n\n<p>The survival improvement becomes even more striking in context: in peer-reviewed publications, the YARTEMLEA treatment was associated with a three- to fourfold reduction in mortality compared to external control cohorts. Among high-risk patients with prior treatment failure, one-year survival reached approximately 50%\u2014a dramatic improvement over historical baseline rates below 20%.<\/p>\n\n\n\n<p>A particularly significant aspect of YARTEMLEA&#8217;s indication is its approval for pediatric patients as young as two years old. In the pediatric clinical experience, results have been equally compelling. When used as first-line therapy, YARTEMLEA-treated children achieved approximately 75% one-year survival. Even among pediatric patients refractory to prior complement-inhibiting therapies, survival rates tripled compared to historical benchmarks\u2014rising from below 20% to approximately 60%.<\/p>\n\n\n\n<p>For pediatric hematology-oncology specialists, this approval reshapes the treatment paradigm. Previously, clinicians managing TA-TMA in children relied on off-label complement inhibitors or defibrotide\u2014treatments of uncertain efficacy and variable safety profiles. YARTEMLEA now offers an FDA-approved, targeted alternative with documented pediatric safety and efficacy.<\/p>\n\n\n\n<p>In the context of high-risk TA-TMA patients, many with multi-organ dysfunction and poor baseline prognosis, YARTEMLEA demonstrated a favorable safety profile. Notably:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>No Boxed Warning and no mandatory REMS (Risk Evaluation and Mitigation Strategy)<\/li>\n\n\n\n<li>No pre-treatment vaccination required, simplifying clinical management<\/li>\n\n\n\n<li>Most common adverse reactions (\u226520%): viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue, and hypokalemia\u2014attributable primarily to the underlying disease severity and transplant-related complications<\/li>\n<\/ul>\n\n\n\n<p>Serious infections occurred in 36% of treated patients, consistent with expectations in immunocompromised HSCT populations. In the expanded access program, no new or unexpected safety signals emerged, providing reassurance regarding long-term safety.<\/p>\n\n\n\n<p>Clinicians are advised to monitor patients with active infections closely for worsening disease, and management should include prompt treatment of any infection. However, the absence of a Boxed Warning and REMS reflects the favorable benefit-risk calculus compared to prior off-label alternatives.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-and-first-mover-advantage\"><span class=\"ez-toc-section\" id=\"Competitive_Landscape_and_First-Mover_Advantage\"><\/span><strong>Competitive Landscape and First-Mover Advantage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>YARTEMLEA&#8217;s approval establishes Omeros as the sole approved player in an entirely new therapeutic category: MASP-2 inhibition for TA-TMA. The company&#8217;s first-mover advantage is substantial. Historically, off-label use of complement inhibitors such as eculizumab (SOLIRIS, targeting C5) or alternative pathway inhibitors provided the only medical interventions, and their efficacy in TA-TMA was suboptimal and variable.<\/p>\n\n\n\n<p>YARTEMLEA&#8217;s targeted lectin pathway inhibition, combined with robust clinical data and now regulatory approval, positions it as the new standard of care for TA-TMA. No direct head-to-head trials comparing YARTEMLEA to eculizumab have been conducted. Still, the compelling real-world survival data and mechanism-of-action advantage provide a strong clinical rationale for preferential use in TA-TMA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-takeaway-a-new-era-in-transplant-care\"><span class=\"ez-toc-section\" id=\"Key_Takeaway_A_New_Era_in_Transplant_Care\"><\/span><strong>Key Takeaway: A New Era in Transplant Care<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA approval of YARTEMLEA represents far more than a regulatory milestone\u2014it marks a clinical paradigm shift. For the estimated 12,000\u201318,000 patients annually who develop TA-TMA after stem cell transplantation, YARTEMLEA offers realistic hope where historically there was only resignation to high mortality. For transplant physicians, YARTEMLEA provides an evidence-based therapeutic tool that directly addresses the pathophysiologic drivers of TA-TMA rather than merely managing symptoms.<\/p>\n\n\n\n<p>YARTEMLEA&#8217;s approval validates Omeros&#8217; scientific focus on complement-mediated diseases. The company&#8217;s pipeline includes multiple complement-targeted programs, positioning it as a leader in this therapeutic area. Future studies may explore YARTEMLEA&#8217;s potential in other complement-driven conditions beyond TA-TMA, though the current indication remains the approved indication.<\/p>\n\n\n\n<p>With a January 2026 U.S. launch, dedicated reimbursement infrastructure, and comprehensive patient support programs, Omeros has positioned YARTEMLEA for rapid clinical uptake and broad access. As the first and only approved therapy for TA-TMA, YARTEMLEA sets a new standard of care\u2014transforming outcomes for adults, children, and families facing this devastating post-transplant complication.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/hematopoietic-stem-cell-transplantation-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/Hematopoietic-Stem-Cell-Transplantation-Market-Outlook-1024x194.webp\" alt=\"Hematopoietic Stem Cell Transplantation Market Outlook\" class=\"wp-image-34257\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/Hematopoietic-Stem-Cell-Transplantation-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/Hematopoietic-Stem-Cell-Transplantation-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/Hematopoietic-Stem-Cell-Transplantation-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/Hematopoietic-Stem-Cell-Transplantation-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/Hematopoietic-Stem-Cell-Transplantation-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/Hematopoietic-Stem-Cell-Transplantation-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine. Omeros Corporation&#8217;s therapeutic advance represents the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This life-threatening complication has historically lacked effective medical interventions and claimed hundreds of lives annually. For transplant physicians and [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34259,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19368,3382,22831,22830],"industry":[17225],"therapeutic_areas":[17238],"class_list":["post-34255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-hematopoietic-stem-cell-transplantation","tag-hsct","tag-hsct-treatment","tag-yartemlea","industry-pharmaceutical","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Omeros\u2019 YARTEMLEA Scores FDA Win<\/title>\n<meta name=\"description\" content=\"The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omeros\u2019 YARTEMLEA Scores FDA Win\" \/>\n<meta property=\"og:description\" content=\"The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T12:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/omeros-yartemlea-for-ta-tma.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Omeros\u2019 YARTEMLEA Scores FDA Win","description":"The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma","og_locale":"en_US","og_type":"article","og_title":"Omeros\u2019 YARTEMLEA Scores FDA Win","og_description":"The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine.","og_url":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-01-05T12:08:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/omeros-yartemlea-for-ta-tma.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma","url":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma","name":"Omeros\u2019 YARTEMLEA Scores FDA Win","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/omeros-yartemlea-for-ta-tma.webp","datePublished":"2026-01-05T12:08:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/omeros-yartemlea-for-ta-tma#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/omeros-yartemlea-for-ta-tma.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/omeros-yartemlea-for-ta-tma.webp","width":466,"height":284,"caption":"omeros-yartemlea-for-ta-tma"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/omeros-yartemlea-for-ta-tma-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hematopoietic stem cell transplantation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HSCT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HSCT Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">YARTEMLEA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">hematopoietic stem cell transplantation<\/span>","<span class=\"advgb-post-tax-term\">HSCT<\/span>","<span class=\"advgb-post-tax-term\">HSCT Treatment<\/span>","<span class=\"advgb-post-tax-term\">YARTEMLEA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 months ago","modified":"Updated 3 months ago"},"absolute_dates":{"created":"Posted on Jan 5, 2026","modified":"Updated on Jan 5, 2026"},"absolute_dates_time":{"created":"Posted on Jan 5, 2026 5:38 pm","modified":"Updated on Jan 5, 2026 3:39 pm"},"featured_img_caption":"omeros-yartemlea-for-ta-tma","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34255"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34255\/revisions"}],"predecessor-version":[{"id":34261,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34255\/revisions\/34261"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34259"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34255"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34255"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}